Advertisement
Collaboration › Details
Ionis Pharmaceuticals–JPMorgan Chase: investor conference, 202401 supply service Ionis presents at JP Morgan Healthcare Conference 2024
Period | 2024-01-08 | |
Region | San Francisco, CA | |
Country | United States (USA) | |
Partner, 1st | Ionis Pharmaceuticals Inc. (Nasdaq: IONS) | |
Group | Ionis Pharmaceuticals (Group) | |
Partner, 2nd | J.P. Morgan Securities LLC | |
Group | JPMorgan Chase (Group) | |
Product | J.P. Morgan 42nd Annual Healthcare Conference 2024 San Francisco | |
Product 2 | RNA-targeting small molecule drugs (rSMs) | |
Person | Monia, Brett P. (Ionis Pharmaceuticals 202312 CEO formerly 201810 COO + SVP Translational Medicine) | |
Person 2 | Walke, D. Wade (Ionis Pharmaceuticals 202312 Investor Relations) | |
Ionis Pharmaceuticals, Inc.. (12/20/23). "Press Release: Ionis to Present at 42nd Annual J.P. Morgan Healthcare Conference". Carlsbad, CA.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Wednesday, January 10, 2024.
A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.
About Ionis Pharmaceuticals
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
Ionis Investor Contact: D. Wade Walke, Ph.D., [email protected], 760-603-2331; Ionis Media Contact: Hayley Soffer, [email protected], 760-603-4679
Record changed: 2024-12-20 |
Advertisement
More documents for Ionis Pharmaceuticals (Group)
- [1] Ionis Pharmaceuticals, Inc.. (12/20/23). "Press Release: Ionis to Present at 42nd Annual J.P. Morgan Healthcare Conference". Carlsbad, CA....
- [2] Ionis Pharmaceuticals, Inc.. (12/18/23). "Press Release: Ionis Announces European Licensing Agreement with Otsuka for Donidalorsen in Hereditary Angioedema". Carlsbad, CA....
- [3] Ionis Pharmaceuticals, Inc.. (9/2/21). "Press Release: Ionis to Present at Upcoming Virtual Investor Conferences". Carlsbad, CA....
- [4] Bicycle Therapeutics plc. (7/13/21). "Press Release: Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics". Cambridge & Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top